BioMarin looks to divest hemophilia gene therapy Roctaviannews2025-10-28T15:29:37+00:00October 28th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
Lilly expands gene therapy work with Adverum acquisitionnews2025-10-24T15:09:02+00:00October 24th, 2025|Endpoints News|
Arcturus announces mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delaynews2025-10-22T18:39:22+00:00October 22nd, 2025|Endpoints News|
Starna Therapeutics raises $44M to advance in vivo CAR-T programs after early clinical datanews2025-10-22T14:19:51+00:00October 22nd, 2025|Endpoints News|
CRISPR Therapeutics says its new gene editing tool is ‘a significant advance’ over prime editing. Prime Medicine disagreesnews2025-10-21T11:00:14+00:00October 21st, 2025|Endpoints News|
Galapagos to exit cell therapy, with loss of 365 jobs and global sites to shutternews2025-10-21T10:56:09+00:00October 21st, 2025|Endpoints News|
Pregene lands up to $1.52B deal with Kite for in vivo therapiesnews2025-10-16T19:25:26+00:00October 16th, 2025|Endpoints News|
Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapiesnews2025-10-15T13:00:10+00:00October 15th, 2025|Endpoints News|
